secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-034159
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed
--------------------------------------------------------------------------------

- Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.
- Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.
- Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.
- Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.
- Human Abuse Potential study over 50% enrolled; topline data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/0000950170-24-034159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/trvi-20240320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer